

Supplementary Table 5. Incidence Rates (Unique Patients with Events Per 100 Patient-Years) for Malignancies in the MDV Database

Group	Malignancy definition 1 ^a			Malignancy definition 2 ^b		
	No.	PY	IR (95% CI)	No.	PY	IR (95% CI)
Group 1 (CS, IM, or TNFi)						
Male	135	9,221.83	1.46 (1.22–1.71)	269	8,909.17	3.02 (2.66–3.38)
Female	104	6,962.25	1.49 (1.21–1.78)	195	6,738.92	2.89 (2.49–3.30)
< 35 yr	11	3,944.42	0.28 (0.11–0.44)	38	3,885.42	0.98 (0.67–1.29)
≥ 35 yr	228	12,239.67	1.86 (1.62–2.11)	426	11,762.67	3.62 (3.28–3.97)
< 50 yr	36	8,940.67	0.40 (0.27–0.53)	117	8,778.50	1.33 (1.09–1.57)
≥ 50 yr	203	7,243.42	2.80 (2.42–3.19)	347	6,869.58	5.05 (4.52–5.58)
< 65 yr	106	13,313.58	0.80 (0.65–0.95)	261	12,966.67	2.01 (1.77–2.26)
≥ 65 yr	133	2,870.50	4.63 (3.85–5.42)	203	2,681.42	7.57 (6.53–8.61)
Group 2 (IM)						
Male	77	4,907.67	1.57 (1.22–1.92)	155	4,735.17	3.27 (2.76–3.79)
Female	57	3,666.67	1.56 (1.15–1.96)	107	3,540.25	3.02 (2.45–3.60)
< 35 yr	6	1,931.25	0.31 (0.06–0.56)	22	1,901.58	1.16 (0.67–1.64)
≥ 35 yr	128	6,643.08	1.93 (1.59–2.26)	240	6,373.83	3.77 (3.29–4.24)
< 50 yr	18	4,588.67	0.39 (0.21–0.57)	63	4,505.25	1.40 (1.05–1.74)
≥ 50 yr	116	3,985.67	2.91 (2.38–3.44)	199	3,770.17	5.28 (4.55–6.01)
< 65 yr	63	7,094.08	0.89 (0.67–1.11)	149	6,910.75	2.16 (1.81–2.50)
≥ 65 yr	71	1,480.25	4.80 (3.68–5.91)	113	1,364.67	8.28 (6.75–9.81)
Group 2-1 (TAC or CyA)						
Male	6	139.67	4.30 (0.86–7.73)	10	133.25	7.51 (2.85–12.16)
Female	9	261.67	3.44 (1.19–5.69)	18	235.00	7.66 (4.12–11.20)
< 35 yr	0	50.83	0.00 (0.00–0.00)	0	50.83	0.00 (0.00–0.00)
≥ 35 yr	15	350.50	4.28 (2.11–6.45)	28	317.42	8.82 (5.55–12.09)
< 50 yr	4	149.92	2.67 (0.05–5.28)	6	144.25	4.16 (0.83–7.49)
≥ 50 yr	11	251.42	4.38 (1.79–6.96)	22	224.00	9.82 (5.72–13.93)
< 65 yr	9	243.08	3.70 (1.28–6.12)	14	233.00	6.01 (2.86–9.16)
≥ 65 yr	6	158.25	3.79 (0.76–6.83)	14	135.25	10.35 (4.93–15.77)
Group 2-2 (6-MP or AZA)						
Male	71	4,768.00	1.49 (1.14–1.84)	145	4,601.92	3.15 (2.64–3.66)
Female	48	3,405.00	1.41 (1.01–1.81)	89	3,305.25	2.69 (2.13–3.25)
< 35 yr	6	1,880.42	0.32 (0.06–0.57)	22	1,850.75	1.19 (0.69–1.69)
≥ 35 yr	113	6,292.58	1.80 (1.47–2.13)	212	6,056.42	3.50 (3.03–3.97)
< 50 yr	14	4,438.75	0.32 (0.15–0.48)	57	4,361.00	1.31 (0.97–1.65)
≥ 50 yr	105	3,734.25	2.81 (2.27–3.35)	177	3,546.17	4.99 (4.26–5.73)
< 65 yr	54	6,851.00	0.79 (0.58–1.00)	135	6,677.75	2.02 (1.68–2.36)
≥ 65 yr	65	1,322.00	4.92 (3.72–6.11)	99	1,229.42	8.05 (6.47–9.64)

(Continued to the next page)

Supplementary Table 5. Continued

Group	Malignancy definition 1 ^a			Malignancy definition 2 ^b		
	No.	PY	IR (95% CI)	No.	PY	IR (95% CI)
Group 3 (TNFi)						
Male	10	1,233.17	0.81 (0.31–1.31)	26	1,204.17	2.16 (1.33–2.99)
Female	10	1,205.17	0.83 (0.32–1.34)	18	1,188.00	1.52 (0.82–2.22)
<35 yr	0	664.50	0.00 (0.00–0.00)	1	663.00	0.15 (0.00–0.45)
≥35 yr	20	1,773.83	1.13 (0.63–1.62)	43	1,729.17	2.49 (1.74–3.23)
<50 yr	4	1,446.00	0.28 (0.01–0.55)	12	1,430.50	0.84 (0.36–1.31)
≥50 yr	16	992.33	1.61 (0.82–2.40)	32	961.67	3.33 (2.18–4.48)
<65 yr	10	2,008.50	0.50 (0.19–0.81)	24	1,981.50	1.21 (0.73–1.70)
≥65 yr	10	429.83	2.33 (0.89–3.77)	20	410.67	4.87 (2.74–7.01)
Group 4 (IM and TNFi)						
Male	10	1,516.50	0.66 (0.25–1.07)	34	1,462.42	2.33 (1.54–3.11)
Female	4	741.00	0.54 (0.01–1.07)	18	709.17	2.54 (1.37–3.71)
<35 yr	0	629.08	0.00 (0.00–0.00)	3	620.50	0.48 (0.00–1.03)
≥35 yr	14	1,628.42	0.86 (0.41–1.31)	49	1,551.08	3.16 (2.28–4.04)
<50 yr	1	1,405.58	0.07 (0.00–0.21)	15	1,381.92	1.09 (0.54–1.64)
≥50 yr	13	851.92	1.53 (0.70–2.36)	37	789.67	4.69 (3.18–6.20)
<65 yr	2	1,984.17	0.10 (0.00–0.24)	27	1,933.92	1.40 (0.87–1.92)
≥65 yr	12	273.33	4.39 (1.91–6.87)	25	237.67	10.52 (6.40–14.64)

^aMalignancy 1 was defined as an ICD-10 code of malignancy (C00–C97 malignant neoplasm or D00–D09 *in situ* neoplasms) along with a cancer management code (B-001-00-03, B-001-00-18, B-001-00-22, B-001-00-23, B-001-00-24, B-005-06, H-007-02) within the same claim month.

^bMalignancy 2 was defined as confirmed diagnosis within two consecutive claims months.

MDV, Medical Data Vision; PY, patient-years; IR, incidence rate (unique patients with events per 100 PY); CI, confidence interval; CS, corticosteroid; IM, immunosuppressant; TNFi, tumor necrosis factor inhibitor; TAC, tacrolimus; CyA, cyclosporine; 6-MP, 6-mercaptopurine; AZA, azathioprine.